483
Custom Compounding CenterFDA 483 - Custom Compounding Center - June 04, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Custom Compounding Center in Little Rock, AR, revealed a significant issue regarding the production of hazardous drugs. The firm failed to implement adequate cleaning procedures, specifically not using an oxidizing agent, to prevent cross-contamination of drug products containing testosterone, estrogen, and morphine. This indicates a serious concern for product quality and patient safety.
- Office
- Dallas District Office
- Person
Open in Dashboard
ID · 74302b65-13ed-4829-85b1-2cf5716e290f